دورية أكاديمية
أعرض في EDS

Intravenous iron for acute and chronic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency: An updated systematic review and meta-analysis.

التفاصيل البيبلوغرافية
العنوان: Intravenous iron for acute and chronic heart failure with reduced ejection fraction (HFrEF) patients with iron deficiency: An updated systematic review and meta-analysis.
المؤلفون: Awad AK; Faculty of Medicine, Ain-Shams University, Cairo, Egypt., Abdelgalil MS; Faculty of Medicine, Ain-Shams University, Cairo, Egypt., Gonnah AR; Imperial College Healthcare NHS Trust, London, United Kingdom. Electronic address: ahmedgonnah18@outlook.com., Mouffokes A; Faculty of Medicine, University of Oran 1 Ahmed Ben Bella, Oran, Algeria., Ahmad U; Punjab Medical college, Faisalabad, Pakistan., Awad AK; Faculty of Medicine, El-Galala University, Suez, Egypt., Elbadawy MA; Faculty of Medicine, Ain-Shams University, Cairo, Egypt., Roberts DH; Lancashire Cardiac Centre, Blackpool, United Kingdom; University of Liverpool, Liverpool, United Kingdom.
المصدر: Clinical medicine (London, England) [Clin Med (Lond)] 2024 May; Vol. 24 (3), pp. 100211. Date of Electronic Publication: 2024 Apr 21.
نوع المنشور: Journal Article; Meta-Analysis; Systematic Review
اللغة: English
بيانات الدورية: Publisher: Elsevier Ltd Country of Publication: England NLM ID: 101092853 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4893 (Electronic) Linking ISSN: 14702118 NLM ISO Abbreviation: Clin Med (Lond) Subsets: MEDLINE
أسماء مطبوعة: Publication: 2024- : [Oxford] : Elsevier Ltd.
Original Publication: London : The College, c2001-
مواضيع طبية MeSH: Heart Failure*/drug therapy , Heart Failure*/physiopathology , Iron*/administration & dosage , Iron*/therapeutic use , Stroke Volume*, Humans ; Administration, Intravenous ; Anemia, Iron-Deficiency/drug therapy ; Iron Deficiencies
مستخلص: Patients with heart failure (HF) and iron deficiency are at increased risk of adverse clinical outcomes. We searched databases for randomised controlled trials that compared IV iron to placebo, in patients with HF with reduced ejection fraction (HFrEF). A total of 7,813 participants, all having HFrEF with 3,998 receiving IV iron therapy, and 3,815 control recipients were included. There was a significant improvement in Kansas City Cardiomyopathy Questionnaire favouring IV iron with MD 7.39, 95% CI [3.55, 11.22], p = 0.0002. Subgroup analysis, based on acute and chronic HF, has displayed a sustained statistical significance. Additionally, a significant increase in the left ventricular ejection fraction % was observed, with MD 3.76, 95% CI [2.32, 5.21], p < 0.00001. A significant improvement in 6-min walk test was noted, with MD 34.87, 95% CI [20.02, 49.72], p < 0.00001. Furthermore, IV iron showed significant improvement in NYHA class, peak VO 2 , serum ferritin, and haemoglobin levels. Finally, despite the lack of difference in terms of all-cause hospitalisation and HF-related death, IV iron was associated with a significant reduction in HF-related, any cardiovascular reason hospitalisations, and all-cause death; which supports the need for implementation of IV iron as a standard of care in patients with HF and iron deficiency.
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
فهرسة مساهمة: Keywords: Acute; Chronic; HFrEF; Intravenous iron; Iron deficiency
المشرفين على المادة: E1UOL152H7 (Iron)
تواريخ الأحداث: Date Created: 20240421 Date Completed: 20240627 Latest Revision: 20240628
رمز التحديث: 20240628
مُعرف محوري في PubMed: PMC11092397
DOI: 10.1016/j.clinme.2024.100211
PMID: 38643833
قاعدة البيانات: MEDLINE
الوصف
تدمد:1473-4893
DOI:10.1016/j.clinme.2024.100211